BOTHELL, Wash. - Immunome, Inc. (NASDAQ:IMNM), a biotechnology firm specializing in the development of cancer therapies, has completed a public offering of 10 million shares of common stock. This includes the full exercise of the underwriters' option to purchase an additional 1.5 million shares, bringing the total gross proceeds to $230 million, before underwriting discounts and commissions and offering expenses.
The shares were priced at $20.00 each, and the offering was conducted under a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2024, which became effective immediately. Both the preliminary and final prospectus supplements, along with the accompanying prospectus, are accessible on the SEC's website.
J.P. Morgan, TD (TSX:TD) Cowen, Leerink Partners, and Guggenheim Securities served as joint book-running managers for the offering, with Wedbush PacGrow acting as the lead manager.
The completion of this offering may bolster Immunome's financial position as it continues to develop its portfolio of cancer therapies. The company's approach includes a variety of drug modalities, such as antibody-drug conjugates (ADCs), radioligand therapies, immunotherapies, and small molecules, tailored to the biology of each target. Immunome's proprietary technology focuses on the rapid screening and functional characterization of novel antibodies and targets, which they believe could lead to transformative therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.